[go: up one dir, main page]

AR023482A1 - Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos - Google Patents

Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos

Info

Publication number
AR023482A1
AR023482A1 ARP000101716A ARP000101716A AR023482A1 AR 023482 A1 AR023482 A1 AR 023482A1 AR P000101716 A ARP000101716 A AR P000101716A AR P000101716 A ARP000101716 A AR P000101716A AR 023482 A1 AR023482 A1 AR 023482A1
Authority
AR
Argentina
Prior art keywords
cd4ol
production
methods
nucleic acids
same
Prior art date
Application number
ARP000101716A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99107611A external-priority patent/EP1067194A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR023482A1 publication Critical patent/AR023482A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un ácido nucleico que codifica un polipéptido quimérico que comprende fragmentos de ácido nucleico que codifican: i) un péptido senal mamífero, ycorriente abajo del mismo: ii) el dominio de vinculacion y de trimerizacion del CD40L, y, corriente abajodel mismo: iii) un separador de 50 a 100 amino ácidosy, corriente abajo del mismo: iv) los dominios transmembranal y de transduccion de las senales, del CD40, es util como agente de terapia de genes para eltratamiento localizado de los tumores solidos.
ARP000101716A 1999-04-16 2000-04-13 Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos AR023482A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99107611A EP1067194A1 (en) 1999-04-16 1999-04-16 Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
EP99113967 1999-07-17

Publications (1)

Publication Number Publication Date
AR023482A1 true AR023482A1 (es) 2002-09-04

Family

ID=26152970

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101716A AR023482A1 (es) 1999-04-16 2000-04-13 Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos

Country Status (8)

Country Link
EP (1) EP1173589A1 (es)
JP (1) JP2003508016A (es)
AR (1) AR023482A1 (es)
AU (1) AU3966200A (es)
CA (1) CA2369820A1 (es)
IL (1) IL144952A0 (es)
NO (1) NO20015003L (es)
WO (1) WO2000063395A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028481A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
WO2002036769A2 (en) * 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1684869B1 (en) 2003-11-04 2011-07-20 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for b cell-related cancers
AU2004287480B2 (en) 2003-11-04 2011-09-15 Novartis Vaccines And Diagnostics, Inc. Use of antagonist anti-CD40 antibodies for treatment of chronic lymphocytic leukemia
DK1682180T3 (da) 2003-11-04 2010-01-11 Novartis Vaccines & Diagnostic Monoklonale antagonist-anti-CD40-antistoffer og fremgangsmåder til anvendelse deraf
DE602004028272D1 (de) 2003-11-04 2010-09-02 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40-monoklonalen antikörpern zur behandlung von multiplem myelom
DK1680141T3 (da) 2003-11-04 2010-11-01 Novartis Vaccines & Diagnostic Fremgangsmåder til terapi til faste tumorer der udtrykker CD40-celleoverfladeantigenet
PT1889065E (pt) 2005-05-18 2013-09-27 Novartis Ag Métodos para o diagnóstico e tratamento de doenças tendo uma componente autoimune e/ou inflamatória
AU2007240507B2 (en) 2006-04-21 2013-07-18 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
PT2066339E (pt) 2006-09-18 2014-10-31 Texas A & M Univ Sys Composições e métodos de potenciar respostas imunes
WO2009059018A1 (en) 2007-10-30 2009-05-07 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
HUE047164T2 (hu) 2007-11-01 2020-04-28 Univ Arkansas Kompozíciók és eljárások eimeria elleni immunválasz fokozására
JP5568807B2 (ja) * 2008-06-06 2014-08-13 静岡県 プロテオミクス解析を用いたメラノーママーカーの同定
NO2525817T3 (es) 2010-01-21 2018-01-06
AU2011264772B2 (en) 2010-06-09 2015-07-16 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce Campylobacter infection
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
EP2956165B1 (en) 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
AR095313A1 (es) 2013-03-15 2015-10-07 Univ Arkansas Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
SG11201809686SA (en) 2016-05-03 2018-11-29 Univ Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
WO2018094309A2 (en) * 2016-11-21 2018-05-24 Nant Holdings Ip, Llc Fractal combination therapy
US20200024326A1 (en) * 2018-06-14 2020-01-23 Nantbio, Inc. Tnf-type receptor-ligand fusion proteins and methods
WO2020073045A1 (en) * 2018-10-05 2020-04-09 Nantcell, Inc. Cd40 and cd40l combo in an adenovirus vaccine vehicle

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
JP3308534B2 (ja) * 1991-10-25 2002-07-29 イミュネックス・コーポレーション 新規なサイトカイン
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells

Also Published As

Publication number Publication date
NO20015003D0 (no) 2001-10-15
CA2369820A1 (en) 2000-10-26
AU3966200A (en) 2000-11-02
EP1173589A1 (en) 2002-01-23
JP2003508016A (ja) 2003-03-04
IL144952A0 (en) 2002-06-30
NO20015003L (no) 2001-10-15
WO2000063395A1 (en) 2000-10-26

Similar Documents

Publication Publication Date Title
AR023482A1 (es) Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
WO2002031134A3 (en) Novel serine protease genes related to dppiv
ATE319818T1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
ATE89006T1 (de) Expression von menschlichem proapolipoprotein a- 1.
DK0559884T3 (da) Rekombinante virusvektorer til ekspression i muskelceller
BR9913331A (pt) Expressão e exportação de inibidores de angiogênese como imunofusinas
WO2002036769A3 (en) Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
RU2002124123A (ru) Модифицированный фактор viii
ATE414775T1 (de) Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren
WO1998031818A3 (en) Tace-like and matrilysin-like polypeptides
ATE310090T1 (de) Gereinigte coprinus laccasen und nukleinsäuren welche dafür kodieren
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
ATE417103T1 (de) Zellulärer rezeptor für hiv-1 vpr essentiell zum g2-m übergang des zellzyklus
DE69837475D1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
Kim et al. Construction of chimeric human epidermal growth factor containing short collagen-binding domain moieties for use as a wound tissue healing agent
PT907731E (pt) Receptores gaba[b] metabotropicos, ligandos especificos dos receptores e suas utilizacoes
WO1998011234A3 (en) Human protein kinases
ATE356145T1 (de) Polypeptide zur regenerierung des nervensystems
ATE288491T1 (de) Polypeptide mit 5-aminolevulinsäure synthaseaktivität und deren nukleinsäuren
ATE317896T1 (de) Polypeptide mit glucanotransferase aktivität und dafür kodierende nukleinsäuren
DE60027928D1 (de) MENSCHLICHES, GEBäRMUTTERKREBS-SPEZIFISCHES SUPPRESSORPROTEIN, FüR DAS PROTEIN KODIERES POLYNUKLEOTID, MIT DEM POLYNUKLEOTID TRANSFORMIERTE ZELLE UND VERFAHREN ZUR UNTERDRüCKUNG DER PROLIFERATION VON KREBSZELLEN UNTER VERWENDUNG DES EXPRESSIONSVEKTORS
MX9806628A (es) Gen de respuesta de diferenciacion terminal mieloide humana novedoso.
WO2000026340A3 (en) Novel nucleic acid molecules encoding opioid growth factor receptors